Premium
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA
Author(s) -
Condoluci A.,
TerzidiBergamo L.,
Forestieri G.,
Moia R.,
Deambrogi C.,
Deodato M.,
Frustaci A. M.,
Merli M.,
Mattarucchi R.,
Autore F.,
Fahrni G.,
Scarfò L.,
Gussetti D.,
Bulian P.,
Zanatta A.,
Spina V.,
Faderl M. R.,
Bruscaggin A.,
Pini K.,
Piffaretti D.,
Koch R.,
Pirosa M. C.,
Cittone M. G.,
Passweg J.,
Cavalli F.,
Zucca E.,
Gerber B.,
Gillessen S.,
Stüssi G.,
Gattei V.,
Ghia P.,
Gregor M.,
Laurenti L.,
Passamonti F.,
Tedeschi A.,
Gaidano G.,
Rossi D.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.45_2880
Subject(s) - ibrutinib , discontinuation , medicine , tolerability , ighv@ , chronic lymphocytic leukemia , oncology , population , retrospective cohort study , adverse effect , leukemia , environmental health